Recombinant Human Indoleamine 2,3-dioxygenase 1(IDO1)

In Stock
Code CSB-EP010996HU
Size US$1726
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP010996HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) IDO1.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP010996HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) IDO1.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names IDO1
Uniprot No. P14902
Research Area Cardiovascular
Alternative Names 3-dioxygenase; I23O1_HUMAN; IDO 1; IDO; IDO-1; IDO1; INDO; indolamine 2,3 dioxygenase; Indole 2 3 dioxygenase; indoleamine 2 3 dioxygenase 1; indoleamine 2 3 dioxygenase; Indoleamine 2,3-dioxygenase 1; Indoleamine pyrrole 2 3 dioxygenase ; Indoleamine-pyrrole 2
Species Homo sapiens (Human)
Source E.coli
Expression Region 1-403aa
Target Protein Sequence MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIESGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVLPRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGFFLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGNPQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMPPAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQQPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLKEG
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 49.3kDa
Protein Length Full Length
Tag Info N-terminal 6xHis-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 3-7 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway
Gene References into Functions
  1. Interference SNHG1 could inhibit the differentiation of Treg cells by promoting miR-448 expression and reducing IDO level, thereby impeding the immune escape of breast cancer . PMID: 29886172
  2. We discuss how small-molecule inhibitors of the tryptophan (Trp) catabolic enzyme indoleamine 2,3-dioxygenase (IDO) represent a vanguard of new immunometabolic adjuvants to safely enhance the efficacy of cancer immunotherapy, radiotherapy, or 'immunogenic' chemotherapy by leveraging responses to tumor neoantigens PMID: 29413421
  3. The role of IDO1-IDO2-AHR pathway in the TLR4-induced tolerogenic phenotype in human dendritic cells has been reported. PMID: 28256612
  4. High coexpression of cytoplasmic IDO1/COX2 was found to be an independent predictor of poor outcome in colorectal cancer patients. PMID: 29853736
  5. Report the crystal structures of IDO1 in complex with its substrate, Trp, an inhibitor, epacadostat, and/or an effector, indole ethanol (IDE). The data reveal structural features of the active site (Sa) critical for substrate activation; in addition, they disclose a new inhibitor-binding mode and a distinct small molecule binding site (Si). PMID: 29167421
  6. IDO decreased glycolysis and glutaminolysis by activating GCN2K, resulting in activation of AMPactivated protein kinase. PMID: 29693118
  7. this review highlights the role of indoleamine-2,3-dioxygenase in normal and pathological pregnancies PMID: 29154462
  8. Data suggest that IDO1 is constitutively expressed in insulin-secreting cells from donors without diabetes; IDO1 appears to be down-regulated in insulin-containing beta-cells from double autoantibody-positive donors and donors with recent-onset type 1 diabetes; this study was conducted on donor tissues obtained from cadavers. PMID: 29945890
  9. Twenty-nine percent (n = 2/7) of the PD-L1 positive poorly differentiated thyroid carcinomas also co-expressed IDO1 PMID: 29372535
  10. In non-ST segment elevation myocardial infarction, the tolerogenic mechanism of the immune response related to IDO production by activated monocytes derived dendritic cells is altered, supporting their role in T-cell dysregulation. PMID: 29278387
  11. These data suggest that the expression of immunosuppressive molecules, including PD-1 ligands and IDO1, by macrophage/microglia may be involved in immune evasion of lymphoma cells. PMID: 29998979
  12. Our data demonstrate that high intratumoral IDO1 mRNA levels correlate with a poor glioblastoma (GBM) patient prognosis. It also confirms the positive correlation between increased GBM IDO1 levels and human-infiltrating T cells PMID: 28751450
  13. Among the 89 patients, CD274, LAG3, and IDO1 expressions in TIICs were observed in 68.6% (61 cases), 13.5% (12), and 28.1% (25) of patients, respectively. CD274, CTLA4, and IDO1 were expressed in tumor cells of 24.7% (22 cases), 4.5% (4), and 72.0% (64) of patients, respectively. PMID: 29520442
  14. Multivariate analysis indicated indoleamine 2,3-dioxygenase (IDO) expression as independent prognostic factors in overall survival (OS). PMID: 29848687
  15. these findings suggest that IDO1 promoter methylation regulates anti-immune responses in breast cancer subtypes and could be used as a predictive biomarker for IDO1 inhibitor-based immunotherapy. PMID: 28264810
  16. main biological and actionable difference between OSCC from NSND and SD lies in the immune microenvironment, suggesting a higher clinical benefit of PD-L1 and IDO1 inhibition in OSCC from NSND PMID: 28460011
  17. An IDO1 inhibitor, epacadostat also demonstrated promising activity in combination with the PD-1 checkpoint inhibitors in other solid tumors, including melanoma, urothelial carcinoma, renal cell carcinoma, and non-small cell lung cancer PMID: 28760910
  18. This first-in-human phase I study investigated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of epacadostat (INCB024360), a potent and selective inhibitor of IDO1 PMID: 28053021
  19. Fumaric acid esters inhibit both IDO expression and enzymatic activity leading to a modulation of tryptophan degradation. PMID: 27376248
  20. Our results highlight the role of COX-2 in constitutive IDO1 expression by human tumors and substantiate the use of COX-2 inhibitors to improve the efficacy of cancer immunotherapy, by reducing constitutive IDO1 expression, which contributes to the lack of T-cell infiltration in "cold" tumors, which fail to respond to immunotherapy PMID: 28765120
  21. this data we have identified the structure of two possible compounds that may be even more potent pharmacological repressors of IDO-1. PMID: 28735627
  22. Prognostic value of IDO in acute myeloid leukemia. PMID: 26762931
  23. These findings indicate that IDO1 has the potential to participate in or contribute to the formation of new capillaries, supporting the applicability of IDO1-targeting molecular therapy in lung cancer. PMID: 28498425
  24. induces PD-L1 expression by melanoma cells PMID: 27121174
  25. PD-L1, IDO-1, and B7-H4 are differentially expressed in human lung carcinomas and show limited co-expression. While PD-L1 and IDO-1 are associated with increased tumor-infiltrating lymphoycte and IFN-gamma stimulation, B7-H4 is not. PMID: 27440266
  26. Data show that indole 23-dioxygenase (IDO) is variably expressed by tumor-infiltrating immune cells or reactive cells rather than lymphoma cells in diffuse large-cell lymphoma (DLBCL). PMID: 26727587
  27. High IDO1 expression is associated with hepatocellular carcinoma. PMID: 26895379
  28. Epacadostat significantly decreases Treg proliferation induced by IDO production from IFN-gamma plus LPS matured human DCs, although the Treg phenotype does not change PMID: 27192116
  29. Inhibition of TOR serine-threonine kinases (mTOR) strongly induced indoleamine 23-dioxygenase 1 (IDO1) expression and activity, corroborating its ability to recruit Treg cells in the tumor microenvironment. PMID: 27174915
  30. up-regulation induces immunosuppression and may enhance the risk of hepatitis C virus and hepatitis B virus induced hepatocellular carcinoma [review] PMID: 28428708
  31. MALAT1-overexpressed MSCs promoted M2 macrophage polarization and this effect was mediated by MALAT1-induced IDO expression, suggesting that MALAT1 may enhance the immunosuppressive properties of MSCs in vivo. PMID: 28176360
  32. this study demonstrated that the downregulation of IDO expression on the endothelial cells of the villous stroma was associated with preeclampsia PMID: 28131097
  33. The data suggest that in Puumala infection, the mechanism responsible for the suppressive effect of IDO is not metabolic control of effector cells but rather the signaling mediated by tryptophan breakdown products, such as kynurenine. PMID: 28057727
  34. These results show IDO is upregulated with RSV infection and this upregulation likely participates with IFN-gamma in inhibition of virus replication and suppression of some host cell responses to infection. PMID: 28963880
  35. IDO role in cancer immune responses [review] PMID: 26517538
  36. This study demonstrated that IDO-1 was elevated in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. PMID: 28859336
  37. The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 PMID: 28731684
  38. Fourier transform infrared (FTIR) and nanosecond time-resolved optical spectroscopy to hIDO1 variants with modified heme pocket structures to identify important amino acid residues that stabilize the substrate in the active site. PMID: 28189796
  39. Thus, our study provides novel insights into the interaction between a small molecule inhibitor INCB14943 and IDO1 protein. The structural information will facilitate future IDO1 inhibitor design. PMID: 28412361
  40. The aim of the present study was to clarify the effect of IDO1induced macrophages on the growth of endometrial stromal cells in endometriosis. IDO1 educated-macrophages may facilitate the survival of retrograde endometrial tissues, and be involved in the pathogenesis of endometriosis. PMID: 28260094
  41. Our results identified FGL2, GAL, SEMA4D, SEMA7A, and IDO1 as new candidate genes that could be involved in MSCs-mediated immunomodulation. FGL2, GAL, SEMA4D, SEMA7A, and IDO1 genes appeared to be differentially transcribed in the different MSC populations. Moreover, these genes were not similarly modulated following MSCs-exposure to inflammatory signals PMID: 28336906
  42. IDO mediated conversion of FOXP3 -T cells to Tregs predominantly occurs in children with inflammatory bowel disease. PMID: 28337881
  43. The study confirmed that high IDO expression in pancreatic adenocarcinoma was related to poor prognosis of patients. These findings provided evidence that IDO was involved in pancreatic adenocarcinoma progression and might serve as a relevant therapeutic target. PMID: 28303855
  44. ver-expression of CTLA4 and IDO1 was significantly associated with biochemical recurrence. Our results provide clues on the mechanisms of tumor development and point to potential biomarkers for early detection and treatment for prostate cancer in young men. PMID: 28027300
  45. IDO1 mRNA expression in cervical cancer PMID: 27761872
  46. Structural Study of a Flexible Active Site Loop in Human Indoleamine 2,3-Dioxygenase and Its Functional Implications. PMID: 27112409
  47. IDO gene expression is a feature of aggressive non-muscle-invasive urothelial cell bladder carcinoma, suggesting a potential immunosuppressive role of IDO PMID: 28314306
  48. Data show that in the absence of indoleamine 2,3-dioxygenase (IDO) inhibition, fatty acid oxidation increased along with increased activity of carnitine palmitoyltransferase I (CPT1). PMID: 27667153
  49. High IDO1 expression is associated with cervical cancer. PMID: 27106797
  50. PSG stimulated IDO activity under the conditions of induction of the monocytes by interferon-gamma. PMID: 27595833

Show More

Hide All

Subcellular Location Cytoplasm, cytosol
Protein Families Indoleamine 2,3-dioxygenase family
Tissue Specificity Expressed in mature dendritic cells located in lymphoid organs (including lymph nodes, spleen, tonsils, Peyers's patches, the gut lamina propria, and the thymic medulla), in some epithelial cells of the female genital tract, as well as in endothelial cell
Database Links

HGNC: 6059

OMIM: 147435

KEGG: hsa:3620

STRING: 9606.ENSP00000430505

UniGene: Hs.840

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1